SPLENIC MARGINAL ZONE LYMPHOMA
Clinical trials for SPLENIC MARGINAL ZONE LYMPHOMA explained in plain language.
Never miss a new study
Get alerted when new SPLENIC MARGINAL ZONE LYMPHOMA trials appear
Sign up with your email to follow new studies for SPLENIC MARGINAL ZONE LYMPHOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Engineered T-Cells take on tough lymphoma in early trial
Disease control OngoingThis phase I trial tests a new approach for patients with high-risk or recurrent non-Hodgkin lymphoma. After a stem cell transplant, participants receive a single infusion of their own genetically modified T-cells designed to recognize and attack cancer cells. The study aims to f…
Matched conditions: SPLENIC MARGINAL ZONE LYMPHOMA
Phase: PHASE1 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
New hope for marginal zone lymphoma: Chemo-Free combo shows promise
Disease control OngoingThis phase II trial tests a combination of two drugs, ibrutinib and rituximab, in people with untreated marginal zone lymphoma, a rare blood cancer. The study aims to see how many patients achieve complete remission after one year and how long they stay cancer-free. About 175 par…
Matched conditions: SPLENIC MARGINAL ZONE LYMPHOMA
Phase: PHASE2 • Sponsor: International Extranodal Lymphoma Study Group (IELSG) • Aim: Disease control
Last updated Jun 27, 2026 12:05 UTC
-
New drug duo aims to slow rare spleen cancer
Disease control OngoingThis study tests whether adding zanubrutinib to standard rituximab works better than rituximab alone for people with a rare lymphoma of the spleen (SMZL) who haven't had treatment yet. About 122 participants will receive either the combo or rituximab alone for up to two years, wi…
Matched conditions: SPLENIC MARGINAL ZONE LYMPHOMA
Phase: PHASE3 • Sponsor: International Extranodal Lymphoma Study Group (IELSG) • Aim: Disease control
Last updated Jun 27, 2026 12:02 UTC
-
New combo therapy shows promise for Tough-to-Treat lymphomas
Disease control OngoingThis early-stage trial tests a new three-drug combination (ibrutinib, rituximab, and bendamustine) in adults with certain types of non-Hodgkin lymphoma that have come back after prior treatment. The main goal is to find the safest dose of ibrutinib when given with the other two d…
Matched conditions: SPLENIC MARGINAL ZONE LYMPHOMA
Phase: PHASE1 • Sponsor: Kami Maddocks, MD • Aim: Disease control
Last updated Jun 27, 2026 12:00 UTC
-
New strategy aims to tame common virus after stem cell transplants
Disease control OngoingThis study tests a modified plan to prevent and treat cytomegalovirus (CMV) infection in people with blood cancers who have had a donor stem cell transplant. CMV is a common virus that can cause serious problems after transplant. The study involves 153 participants and looks at w…
Matched conditions: SPLENIC MARGINAL ZONE LYMPHOMA
Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated Jun 27, 2026 09:00 UTC